Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone203-624-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15 million
Profitability
Miscellaneous
Employees88
OptionableOptionable
Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions
What is Achillion Pharmaceuticals' stock symbol?
Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."
How were Achillion Pharmaceuticals' earnings last quarter?
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. View Achillion Pharmaceuticals' Earnings History.
When is Achillion Pharmaceuticals' next earnings date?
What price target have analysts set for ACHN?
1 Wall Street analysts have issued 12-month target prices for Achillion Pharmaceuticals' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Achillion Pharmaceuticals' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 110.1% from the stock's current price. View Analyst Price Targets for Achillion Pharmaceuticals.
What is the consensus analysts' recommendation for Achillion Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals.
Has Achillion Pharmaceuticals been receiving favorable news coverage?
Media headlines about ACHN stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the company's share price in the immediate future.
Are investors shorting Achillion Pharmaceuticals?
Achillion Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 13,706,546 shares, an increase of 29.3% from the January 15th total of 10,598,235 shares. Based on an average daily trading volume, of 2,152,873 shares, the short-interest ratio is currently 6.4 days. Approximately 10.2% of the company's shares are short sold. View Achillion Pharmaceuticals' Current Options Chain.
Who are some of Achillion Pharmaceuticals' key competitors?
Some companies that are related to Achillion Pharmaceuticals include Spectrum Pharmaceuticals (SPPI), Cambrex (CBM), Esperion Therapeutics (ESPR), Phibro Animal Health (PAHC), Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), Vanda Pharmaceuticals (VNDA), Deciphera Pharmaceuticals (DCPH), Puma Biotechnology (PBYI), Rhythm Pharmaceuticals (RYTM), Epizyme (EPZM), Kiniksa Pharmaceuticals (KNSA), Alder Biopharmaceuticals (ALDR), Tricida (TCDA) and Advanz Pharma (CXRXF).
Who are Achillion Pharmaceuticals' key executives?
Achillion Pharmaceuticals' management team includes the folowing people:
- Mr. Joseph Truitt, Pres, CEO & Director (Age 54)
- Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 64)
- Ms. Keri Lantz, Interim Principal Financial Officer, Principal Accounting Officer, Controller & VP of Fin. (Age 44)
- Mr. Paul Firuta, Exec. VP & COO (Age 53)
- Mr. Brian R. DiDonato, VP of Investor Relations & Corp. Communications (Age 52)
Who are Achillion Pharmaceuticals' major shareholders?
Achillion Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include RTW Investments LP (9.92%), BlackRock Inc. (8.73%), Dimensional Fund Advisors LP (5.37%), South Dakota Investment Council (1.33%), Northern Trust Corp (1.17%) and Geode Capital Management LLC (1.12%). View Institutional Ownership Trends for Achillion Pharmaceuticals.
Which major investors are selling Achillion Pharmaceuticals stock?
ACHN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Bank of America Corp DE, Squarepoint Ops LLC, Rhenman & Partners Asset Management AB, Tekla Capital Management LLC, Barclays PLC, Virtus ETF Advisers LLC and GSA Capital Partners LLP. View Insider Buying and Selling for Achillion Pharmaceuticals.
Which major investors are buying Achillion Pharmaceuticals stock?
ACHN stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, 683 Capital Management LLC, South Dakota Investment Council, Mirae Asset Global Investments Co. Ltd., D. E. Shaw & Co. Inc., Two Sigma Advisers LP, Dimensional Fund Advisors LP and BlackRock Inc.. View Insider Buying and Selling for Achillion Pharmaceuticals.
How do I buy shares of Achillion Pharmaceuticals?
Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achillion Pharmaceuticals' stock price today?
One share of ACHN stock can currently be purchased for approximately $2.38.
How big of a company is Achillion Pharmaceuticals?
Achillion Pharmaceuticals has a market capitalization of $329.91 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-85,230,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Achillion Pharmaceuticals employs 88 workers across the globe.
What is Achillion Pharmaceuticals' official website?
How can I contact Achillion Pharmaceuticals?
Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.
MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
